Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma

Current Eye Research

Volumn 32, Issue 7-8, 2007, Pages 659-667

  Park, Juyoung ^a   Franco, Robert S ^b   Augsburger, James J ^b   Banerjee, Rupak K ^a  

^a University of Cincinnati   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

2 methoxyestradiol (2ME2); Intraocular lymphoma (IOL); Methotrexate (MTX); Primary central nervous system lymphoma (PCNSL); Tissue culture

Indexed keywords

2 METHOXYESTRADIOL; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; METHOTREXATE; PROPIDIUM IODIDE; TETRAZOLIUM;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLORIMETRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOMA CELL LINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANNEXIN A5; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; METHOTREXATE; TUMOR CELLS, CULTURED;

EID: 34548606407     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701473244     Document Type: Article

References (37)

1. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92:261-266.
2. Paulus W. Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol. 1999;43:203-208.
3. Hochberg FH, Miller DC. Primary central nervous system lymphoma (review). J Neurosurg. 1998;68:835-853.
4. Chamberlain MC. Current concepts in legtomeningeal metastasis. Curr Opin Oncol. 1992;4:533-539.
5. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10:635-643.
6. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer. 1995;75:2919-2931.
7. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115:1152-1156.
8. Smet MD, Vance VS, Hohler D, Solomon D, Chan CC. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol. 1998;83:448-451.
9. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709-1716.
10. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. High-dose methotrexate for intraocular lymphoma. Clinical Cancer Research. 2003;9:711-715.
11. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Research. 2004;64:5804-5811.
12. Ferreri AJM, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol. 2000;11:927-937.
13. Ball P, Haupt M, Knuppen R. Biogenesis and metabolism of catechol estrogens in vitro. In: Merriam GR, Lipsett MB, eds. Catechol Estrogens. New York: Raven Press, 1983;91-104.
14. Martucci CP. Metabolic fate of catechol estrogens. In: Merriam GR, Lipsett MB, eds. Catechol Estrogens. New York: Raven Press, 1983;115-122.
15. Marr AK, Thamm DH, Kurzman ID, Vail DM, MacEwen EG. In vitro effects of 2-methoxyestradiol on canine tumour cells. Veterinary and Comparative Oncology. 2003;1:159-167.
16. Pribluda VS, Gubish ER, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous anti-angiogenic and anti-proliferative drug candidate. Cancer and Metastasis Reviews. 2000;19:173-179.
17. Golebiewska J, Rozwadowski P, Spodnik JH, Knap N, Wakabayashi T, Wozniak M. Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells. Acta Biochimica Polonica. 2002;49:59-65.
18. Fotsis T, Zang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature (London). 1994;368:237-239.
19. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicines site. Proc Natl Acad Sci USA. 1994;91:3964-3968.
20. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS. 2002;531:141-151.
21. Carothers AM, Hughes SA, Ortega D, Bertagnolli MM. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Letters. 2002;187:77-86.
22. Qanungo S, Basu A, Das M, Haldar S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene. 2002;21:4149-4457.
23. Attalla HTP, Makela H, Adlercreutz H, Andersson LC. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Comm. 1996;228:467-473.
24. Josefsson E, Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arth Rheum. 1997;40:154-163.
25. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Can Res. 1997;57:81-86.
26. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors A and B. Can Res. 2002;62:3691-3697.
27. Ben-Bassat H, Pollack A, Shlomai Z, et al. Farage, a novel early B cell lymphoma cell line with trisomy 11. Leuk Lymph. 1992;6:513-521.
28. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol. 1991;25:306-318.
29. Pinedo HM, Zaharko DS, Bull JM, Chabner BA. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Can Res. 1976;36:4418-4424.
30. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Systhesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, and endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem. 1995;9;38:2041-2049.
31. Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chan CC, Nussenblatt RB, Robinson MR. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol. 2001;119:1518-1524.
32. Reiser F, Way D, Bernas M, Witte M, Witte C. Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Exp Bio Med. 1998;219:211-216.
33. Yamasaki E, Soma Y, Kawa Y, Mizoguchi M. Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells. Br J Dermatol. 2003;149:30-38.
34. Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002;100:2187-2194.
35. Margolis L, Fraser R, Lichter A, Char DH. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer. 1980;45:688-692.
36. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
37. Mittra RA, Pulido JS, Hanson GA, et al. Primary ocular Epstein-Barr virus-associated non-Hodgkins lymphoma in a patient with AIDS: a clinicopathologic report. Retina. 1999;19:45-50.